Global Markets 2011 - Special Report

Mike Huckman

More

  • I hate goodbyes. So, rather than get all sappy and sentimental, I'm just gonna say, "Thank you."

  • My last day at CNBC is May 7th. I've decided to make a career change. Because my next act will include working within the health care sector, to avoid even the appearance of a conflict in my remaining days here at CNBC, I won't be blogging or reporting anymore about stock-related stories on my previous beat.

  • The Life & Times of Tim

    With a nod to my colleague Jane Wells' "Funny Business" blog and at the risk of getting armies of pharma sales reps mad at me, I am sending out a DVR alert for Episode 15 from the second season of an HBO animated comedy called, "The Life And Times Of Tim."

  • Twitter

    A few months ago I blogged that Pops had taken the bold step of jumping on Twitter and actually tweeting (that's Twitter-speak for sending out messages of 140 characters or less.) Well, now, a sell-side biotech analyst is tweeting, too.

  • Brad Stevens

    Butler's Gordon Hayward threw a closing buzzer, half-court, long shot against Duke last night. It was oh-so-close. But when Butler coach Brad Stevens threw caution to the wind 10 years ago, it turns out it was a slam dunk.

  • Ray Elliott put in less than six months on the job last year at Boston Scientific as the medical device maker's new CEO. But, according to "The New York Times," in that short amount of time Elliott received enough total compensation to make him the second-highest paid head honcho behind only Oracle's Larry Ellison (albeit a distant #2.)

  • fda_medicine_200.jpg

    FDA advisory committee votes sometimes end in confusion. First, because the actual vote often gets all convoluted and recounted as some panelists hem and haw about voting thumbs up or thumbs down and try to equivocate their decision. And second, because no matter how many times I've explained it to people here, the votes get misread and miscommunicated as actual approval or rejection of a drug versus a recommendation that the FDA clear or spike a drug.

  • But, oh! The irony. At a meeting designed to convince the Street the company is well on its way to correcting a major manufacturing problem, a simple technical glitch keeps executives from conveying that message to a broader, off-site audience.

  • Miles White

    You need to buy the paper edition for $5 or subscribe to the website to see it for yourself, but Barron's has put only one biopharma honcho on its annual list of the world's top-30 CEOs.

  • Vivus announced this morning that an FDA advisory committee is tentatively scheduled to take a look at its diet drug Qnexa on Thursday, July 15th.